Latest News
-
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
A step forward for gene editing: CRISPR-Cas9 and HD
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
A potential HD biomarker has been uncovered in a recent clinical study
-
Huntington's Disease Therapeutics Conference 2017 – Day 3
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta
-
Huntington's Disease Therapeutics Conference 2017 – Day 2
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 2
-
Huntington's Disease Therapeutics Conference 2017 – Day 1
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-
Enemy at the gates – huntingtin disrupts nuclear transport
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease